文献速递核素与放射性配体治疗放射性药物与辐射防护

基于生物半衰期异速外推法估算225Ac-NOTA-曲妥珠单抗的人体剂量学

225Ac-NOTA-trastuzumab human dosimetry using inter-radionuclide and biological half-life based allometric extrapolation method.
PubMed 文献 · EJNMMI Res · 2026-01-03

本研究利用64Cu-NOTA-曲妥珠单抗的小鼠生物分布数据,结合小鼠到人体外推与Bateman方程,估算225Ac-NOTA-曲妥珠单抗的人体等效剂量并考虑子体核素贡献。方法M3(小鼠驻留时间与生物半衰期异速外推)估算的驻留时间与人体驻留时间显著配对。225Ac及其子体在同一器官内驻留时间非常相似,肝脏驻留时间最高为2.57×10−2 MBq·h/MBq,胃最低为8.24×10−4 MBq·h/MBq,估算有效剂量为6.64×10−1 mSv/MBq。

要点

  • 基于生物半衰期异速外推法估算的驻留时间与临床数据一致。
  • 225Ac及其子体在同一器官内驻留时间非常相似。
  • 225Ac-NOTA-曲妥珠单抗估算有效剂量为6.64×10−1 mSv/MBq。

核心结论

  • 基于生物半衰期异速外推法估算225Ac-NOTA-曲妥珠单抗人体等效剂量,结果与临床数据一致。
  • 结合Bateman方程校正可考虑子体核素剂量贡献,从临床前分布数据计算人体驻留时间。

研究设计与样本

  • 利用64Cu-NOTA-曲妥珠单抗的小鼠生物分布数据,采用小鼠到人体外推与Bateman方程联合模型估算225Ac-NOTA-曲妥珠单抗人体等效剂量。

主要发现

  • 方法M3(小鼠驻留时间与生物半衰期异速外推)估算的驻留时间与人体驻留时间显著配对。
  • 225Ac及其子体在同一器官内驻留时间非常相似。
  • 225Ac-NOTA-曲妥珠单抗肝脏驻留时间最高,为2.57×10−2 MBq·h/MBq;胃最低,为8.24×10−4 MBq·h/MBq。
  • 225Ac-NOTA-曲妥珠单抗估算有效剂量为6.64×10−1 mSv/MBq。

临床怎么用

  • 可利用临床前64Cu-NOTA-曲妥珠单抗生物分布数据外推225Ac标记药物的驻留时间与有效剂量,并考虑子体核素贡献。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Image-based dosimetry of 225Ac is challenging due to its high cytotoxicity, which limits the administered dose and, consequently, restricts the number of photons available for imaging. This study aimed to estimate human equivalent dose of 225Ac-NOTA-trastuzumab while considering dose contribution from daughter radionuclides using mouse biodistribution of 64Cu-NOTA-trastuzumab by utilizing a combined model of mouse-to-human extrapolation and Bateman equation. RESULTS: Residence times estimated by methods M3, which involved mouse residence times and biological half-life allometry was significantly paired to human residence times. The proposed method demonstrated that the residence time of 225Ac and its progeny was very similar within the same organ. The highest residence time of 225Ac-NOTA-trastuzuamb was observed in liver, measuring 2.57 × 10− 2 MBq·h/MBq, while stomach exhibited the lowest residence time of 8.24 × 10− 4 MBq·h/MBq. The estimated effective dose of 225Ac-NOTA-trastuzumab was 6.64 × 10− 1 mSv/MBq. CONCLUSIONS: In this study, we estimated human equivalent dose of 225Ac-NOTA-trastuzumab using preclinical data of 64Cu-NOTA-trastuzumab. Extrapolation method based on biological half-life allometry produced results consistent with clinical data. To account for dose contribution from daughter radionuclides, extrapolation method was corrected with the solution of Bateman equation. Our proposed method is capable of calculating the radiopharmaceutical’s residence time in human from preclinical distribution data while considering the contribution of daughter radionuclide.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Almaslamani M, Kim K, Kim KI, et al. 225Ac-NOTA-trastuzumab human dosimetry using inter-radionuclide and biological half-life based allometric extrapolation method. EJNMMI Res. 2026. PMID: 41483377. doi:10.1186/s13550-025-01369-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。